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Summary.-Mammary tumours were induced in 3 groups of male Long-Evans rats
by a series of 6 fortnightly gastric intubations of 7, 12-dimethylbenzanthracene.
Two weeks before the initial carcinogen treatment one group of rats was grafted
with 3 pituitary homografts underneath the kidney capsule of each recipient (hyper-
prolactinaemia). A second group, 2 weeks before the initial carcinogen treatment
and for the duration of the study (35 weeks), were injected 4xweekly with 2-Br-oa-
ergocryptine (CB-154) (hypoprolactinaemia). A third group of rats served as
controls. A significant increase in the incidence of mammary tumours and a
reduced latency period of tumour appearance in the hyperprolactinaemia group,
when compared with the controls, were observed in this study. Mammary tumour
incidence and latency period of tumour appearance in the hypoprolactinaemia group,
however, did not differ significantly from controls. Thus, an increased secretion of
pituitary prolactin in rats appears to be an important enhancing endocrinic condition
in carcinogenesis of the male mammary gland.
THE ADMINISTRATION of 7,12-dimethyl-
benzanthracene (DMBA) has been a
standard procedure for over a decade for
the rapid production of mammary carci-
nomata in laboratory rats (Huggins, 1965),
an experimental model which in certain
respects resembles human breast cancer
(Dao, 1964; Middleton, 1965). In the
female rat, this procedure results in mam-
mary carcinomata of high yield that
are hormone responsive. The hormonal
dependency ofthese carcinomata has been
studied intensely and it appears that the
major influential hormones in this process
are oestrogen and prolactin (Daniel and
Prichard, 1964; Welsch, Clemens and
Meites, 1969). Growth hormone (Young,
1961; Li and Yang, 1974) and progesterone
(McCormick and Moon, 1967; Jabara and
Harcourt 1970) may also be important
contributing hormonal factors in this
neoplastic process.
Inthe male rat, mammarycarcinomata
are much more difficult to induce with
hydrocarbon carcinogens, the yield being
considerably less than that observed in
the female rat (Dao and Greiner, 1961).
The hormones prerequisite for mammary
carcinogenesis in the male rat are not
known. The purpose ofthis study, there-
fore, is to determine whetherornotmarked
changes in secretory activity of pituitary
prolactin are influential in male mammary
carcinogenesis as they most certainly are
in the female rat.
MATERIALS AND METHODS
One hundred and fourteen male Long-
Evans rats were housed in a temperature
controlled (75 + 2°F) and light controlled
(14 h/day) room and fed a diet ofWayne Lab
Blox (Allied Mills, Chicago, Ill.). At 30-45
days ofage, all rats were divided into 3 groups
and each rat treated as follows: Group I,
controls, were injected s.c. 4 x weekly (M, W,
F and S) with saline. Group II, hypo-
prolactinaemia, were injected 4 x weekly
with 2-Br-o-ergocryptine (CB-154). Group
III, hyperprolactinaemia, were grafted under-
neath the kidney capsule with 3 pituitary
homografts and injected s.c. 4 x weekly with
saline. The CB-154 solution was adminis-C. W. WELSCH, G. LOUKS, D. FOX AND C. BROOKS
tered at a dose of 0-4 mg/100 g body weight
and was prepared by dissolving the ergot in
a minimal amount of 100% ethanol and
diluting with 0-9% NaCl solution so that the
final concentration was 2-0 mg CB-154/ml.
The pituitary donor rats were of the same
strain and age astherecipients, butofopposite
sex. All animals ofGroups I and II received
sham operations.
Twelve days after the beginning of
treatments, all rats were given an initial
single i.g. intubation of 7,12-dimethylbenz-
anthracene (DMBA) (10 mg/rat, dissolved in
sesame oil) and at 2-week intervals thereafter
for a total of 6 gastric intubations. After
thelastgastricintubationofDMBAallanimals
were examined weekly for palpable mammary
tumours. The meanlatencyperiodoftumour
appearance was determined by calculating
the average number of days from the initial
day of carcinogen treatment to detection
of each palpable tumour. Each mammary
tumour, upon first detection, was excised,
fixed in 10% formalin and stained with
haematoxylin and eosin for histological
evaluation.
All surviving rats were killed 35 weeks
after the initial day of treatment. Blood
was obtained from each rat and analysed
by radioimmunoassay for prolactin. Differ-
ences between mean blood prolactin levels
and between mean latency periods of mam-
mary tumour appearance were evaluated
statistically byStudent's "t" test and tumour
incidence was evaluated statistically by Chi-
square analysis.
RESULTS
The results ofthis study are illustrated
in the Table. Approximately twice the
number of mammary tumours were
observed in the pituitary grafted group
(28) compared with the CB-154 treated
group (14) or the control group (15)
(P<0-001). Furthermore, the mean
latencyperiodofmammarytumourappear-
ance was significantly (P<0-05) shortened
in the pituitary grafted animals (187 days)
when compared with the controls (230
days). Of the 28 mammary tumours
observed in the pituitary grafted rats,
there were 12 adenocarcinomata, 9 sar-
comata, 5 benign adenomata and 2 benign
fibromata. Of the 14 mammary tumours
in the CB-154 treated group, there were
3 adenocarcinomata, 6 sarcomata, no
benign adenomata and 5 benign fibromata.
Ofthe 15 mammary tumours in the control
group, there were 3 adenocarcinomata,
4 sarcomata, 1 benign adenoma and 7
benign fibromata. Blood prolactin values
were significantly (P<0-001) increased in
the pituitary grafted group and decreased
in the CB-154 treated group. No sig-
nificant effect ofthese treatments on body
TABLE.-Inftuence ofProlactin on 7,12-Dimethylbenzanthracene (DMBA) Induced
Mammary Tumorigenesis in the Male Long-Evans Rat
No. of rats
(beginning of study)
Mean body wt (g)
(beginning of study)
No. of rats
(termination of study)
Mean body wt (g)
(termination of study)
Mean serum prolactin
levels (ng/ml)*
No. of mammary
tumours per groupt
Mean latency period of
mammary tumour appearance
(days)*
Group I
Controls
38
66
14
Group II
CB-154 treated
38
61
14
390
12 4± 1 *8a
15a
230'0+11 ld
402
2-3±0- 3b
14a
204-6±13 7
Group III
Pituitary grafts
38
61
12
396
40 1±8-3C
28b
186-5±15-3e
* Mean ± standard error of the mean.
t See text for histopathological evaluation.
P<0 001, a/b, a/c, b/c.
P<0 05, d/e.
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weighlt g(ainis was observed. A few rats in
each group developed an erythroblastic
leukaemia, a response characteristic of
this strain ofratwhentreatedwith carcino-
genic hydrocarbons, as previously reported
(Huggins and Sugiyama, 1966).
DISCUSSION
The restults of this study show clearly
that hydrocarbon induced mammary
tumorigenesis in the male rat is markedly
enhanced by concurrently increasing pitui-
tary prolactin secretion. There were
approximately 4times more carcinomatous
neoplasias and twice the number of
sarcomatous outgrowths in the mammary
glands of the hyperprolactinaemia group
than in the control group. Although the
total number ofbenign mammary tumours
in the hyperprolactinaemia group was
comparable with the control group, there
was a striking shift in the histological
characteristics of these tumours, i.e.,
nearly all the benign tumours in the con-
trol group were fibromatous whereas most
of the benign tumours in the hyper-
prolactinaemia group had adenomatous
microscopic features.
Unlike the female rat, hydrocarbon
induced mammary tumorigenesis in the
male rat has been rarely studied. Dao and
associates (Dao and Sunderland, 1959;
Dao and Greiner, 1961) showed that a
series of pulse injections of 3-methylchol-
anthrene (MCA) to intact male rats failed
to induce mammary tumours. However,
if these rats were castrated a few tumours
would develop and if the castrated rats
were grafted with ovaries, tumour incid-
enceinthese maleratswouldrisemarkedly,
nearly comparable with that observed
in MCA treated female rats. These earlier
studies clearly illustrated the inhibitory
effects of androgens and the stimulatory
effects of oestrogens in carcinogen induced
male mammary tumorigenesis. The
results of our study, using a more potent
carcinogen, provide the first evidence
that prolactin, in addition to oestrogen,
isastimulatory hormonein male mammary
tumorigenesis in carcinogen treated rats.
These results are in accord with the earlier
report of Hagen and Rawlinson (1964)
who showed that 8pontaneous mammary
tumorigenesis in the male mouse can be
increased by the grafting of multiple
pituitaries to these animals.
Grafting of pituitaries to sites distant
from the hypothalamus has long been a
procedure recognized as an effective means
to produce hyperprolactinaemia (Everett,
1954; Welsch, Negro-Vilar and Meites,
1968). The grafts continuously secrete
large amounts of prolactin and reduced
amounts, if any, of all other pituitary
hormones. In accord, approximately 3
times the level of prolactin was found
in the serumofthegraftedratsinthisstudy
when compared with the controls. More
recently, it has been shownthatthe admin-
istration of a number of ergot alkaloids
or ergoline derivatives can induce hypo-
prolactinaemia in rats (Welsch et al., 1971;
Clemens et al., 1974) as well as in man
(Lutterbeck et al., 1971). CB-154 appears
to be one of the most effective prolactin
suppressors currently available (Brooks
and Welsch, 1974). Although the male
rat normally secretes relatively small
amounts of prolactin at least when com-
pared with the female rat, chronic treat-
ment of male rats with CB-154 in this
study did significantly reduce the serum
levels of this hormone in these animals.
It is interesting that such a reduction
in serum prolactin levels did not signifi-
cantly influence mammary tumorigenesis
in these animals. This is quite uflike
what is observed in the female rat Where
an ergot alkaloid induced hypoprolactin-
aemia results in a striking reduction in
both the development (Clemens and Shaar,
1972) and growth (Cassell, Meites and
Welsch, 1971; Stahelin, Burckhardt-
Visher and Fliuekiger, 1971) of DMBA
induced mammary carcinomata. Fur-
thermore, in female mice, the development
of either spontaneous (Welsch andGribler,
1973; Welsch, Gribler and Clemens, 1974)
or induced (Yanai and Nagasawa, 1971)
mammary carcinomata can be virtually
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prevented or sharply curtailed by an ergot
alkaloid induced hypoprolactinaemia. It
is probable that drug induced suppression
of the secretion of this hormone in males
does not result in a marked differential
inthetotalquantityofthehormonesecreted,
because the male rat normally secretes
relatively small amounts of prolactin.
Breast cancerigenesis in the human
male is relatively uncommon (Hayward,
1970). It has been hypothesized that
the aetiology of this disease in males may
be related to altered steroid metabolism
leading to a heightened oestrogenicity
(El-Gazayerli and Abdel-Aziz, 1963).
Indeed, the administration of oestrogens
to male patients has been reported to
result in an increase in breast cancer
development (O'Grady and McDivitt,
1969). Although prolactin has been
implicated in cancerigenesis of the human
female breast (Salih et al., 1972; Kwa
et al., 1974), it remains to be determined
whether or not this hormone has a role
in tumorigenesis ofthe human male breast.
The results of this study provide convinc-
ing evidence that in the male rat treated
with carcinogenic hydrocarbons, an
elevation in the secretion of prolactin
significantly increases mammary carcino-
genesis.
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